Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
Arlington, VA – Tuesday, October 23, 2007 – Champions Biotechnology, Inc. (OTC Bulletin Board:CSBR), a development stage biotechnology company, announced today the appointment of Dr. David Sidransky, Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine, to serve as Chairman of the Board, replacing James Martell who has served in that capacity since 1991. Dr. Sidransky was appointed to serve on the Company’s Board of Directors in August 2007. He is the largest shareholder of Champions Biotechnology.
Dr. Sidransky, 47, is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. He is Professor of Oncology, Otolaryngology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at John Hopkins University and Hospital. Dr. Sidransky is one of the five most highly cited researchers in clinical and medical journals in the world, in the field of oncology during the past decade, with over 300 peer-reviewed publications. He has contributed more than 40 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents.
Dr. Sidransky has served as Vice Chairman of the Board of Directors, and presently is a director of ImClone. He is a Vice Chairman of Alfacell and serves on the Board of Directors of Xenomics. He is serving and has served on scientific advisory boards of MedImmune, Roche, Amgen and Veridex, LLC (a Johnson & Johnson diagnostic company), among others. Dr. Sidransky serves as Director (2005-2008) of American Association for Cancer Research (AACR). He was the chairperson of AACR International Conferences (2006 and 2007) on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Individualized Treatment. Dr. Sidransky is the recipient of a number of awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians and the 2004 Hinda and Richard Rosenthal Award from the American Association of Cancer Research.
“I am highly honored by the great privilege of having Dr. Sidransky lead the company into the future as its Chairman ” said James Martell, President and CEO of Champions Biotechnology. “Dr. Sidransky is a creative, out-of-the box thinker with wide-ranging academic and business background and extensive contacts within the pharmaceutical industry, academia and government. He will provide the vision, direction, drive and inspiration to grow our Company into what we hope will be one of the leading biotechnology players in the world, in the fight against disease. ”
Champions Biotechnology is actively engaged, as stated in the Company’s most recent 10-QSB filing, in pursuit of long term funding, additional opportunities to grow and strengthen the Company, development of management team, selection and appointment of new members to the Board of Directors and formation of a Scientific Advisory Board. The Company looks forward to reporting updates regarding any material events and corporate changes in the future.
CNN/TIME – America’s Best Thomson Scientific Names Doctors of the Decade, 1995-2005 -Thomson Scientific Molecular Diagnostics in Cancer Therapeutic Development